Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (171-180 of 420) with videos related to

Pageof 42
Sort By:
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Plos One|May 17, 2018
Integrative omics to detect bacteremia in patients with febrile neutropeniaRachel S Kelly, Jessica Lasky-Su, Sai-Ching J Yeung, et al.
Leukemia & Lymphoma|April 19, 2018
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey<sup>.</sup>Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
JAMA|June 11, 2009
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trialsJohn Koreth, Richard Schlenk, Kenneth J Kopecky, et al.
Leukemia Research|July 14, 2023
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemiaMaximilian Stahl, Gerard Giblin, Yiwen Liu, et al.
Nature Communications|August 10, 2021
FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunityVijayashree Mysore, Xavier Cullere, Joseph Mears, et al.
Pageof 42

Showing results (171-180 of 420) with videos related to

Sort By:
Pageof 42
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Plos One|May 17, 2018
Integrative omics to detect bacteremia in patients with febrile neutropeniaRachel S Kelly, Jessica Lasky-Su, Sai-Ching J Yeung, et al.
Leukemia & Lymphoma|April 19, 2018
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey<sup>.</sup>Maximilian Stahl, Alexander Pine, Jeanne E Hendrickson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.
Blood|August 14, 2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Bayard L Powell, Barry Moser, Wendy Stock, et al.
JAMA|June 11, 2009
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trialsJohn Koreth, Richard Schlenk, Kenneth J Kopecky, et al.
Leukemia Research|July 14, 2023
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemiaMaximilian Stahl, Gerard Giblin, Yiwen Liu, et al.
Nature Communications|August 10, 2021
FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunityVijayashree Mysore, Xavier Cullere, Joseph Mears, et al.
Pageof 42